Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 6/20 | 0.34 |
| ▸ | CTSS | P25774 | 4/20 | 0.34 |
| ▸ | CTSL | P07711 | 3/20 | 0.34 |
| ▸ | CTSV | O60911 | 2/20 | 0.34 |
| ▸ | CTSK | P43235 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5870275 | 0.83 | CTSC (0.43) | HPGDSMN1; SMN2CTSSCTSLCTSV | |
| SCHEMBL5870525 | 0.83 | OPRK1 (0.33) | SMN1; SMN2CTSSCTSLCTSVCTSK | |
| SCHEMBL5870374 | 0.81 | TSHR (0.38) | ALDH1A1HPGDSMN1; SMN2TDP1TSHR | |
| SCHEMBL5870207 | 0.81 | TSHR (0.37) | ALDH1A1TDP1TSHRCTSSCTSL | |
| SCHEMBL5870549 | 0.81 | CTSL (0.37) | ALDH1A1SMN1; SMN2CTSSCTSLCTSV | |
| SCHEMBL5870371 | 0.79 | C5AR1 (0.36) | SMN1; SMN2CTSSCTSLCTSVMAPT | |
| SCHEMBL5870316 | 0.76 | ALDH1A1 (0.46) | ALDH1A1HPGDSMN1; SMN2TDP1TSHR | |
| SCHEMBL5870320 | 0.76 | ALDH1A1 (0.46) | ALDH1A1HPGDSMN1; SMN2TDP1TSHR | |
| SCHEMBL4448207 | 0.76 | ALDH1A1 (0.46) | ALDH1A1HPGDSMN1; SMN2TDP1TSHR | |
| SCHEMBL5870104 | 0.76 | HPGD (0.38) | ALDH1A1HPGDSMN1; SMN2TDP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7132449-B2 | Inhibitors of cruzipain and other cysteine proteases | AMURA THERAPEUTICS LIMITED (GB) | 2006-11-07 | — | — | US | disclosed |
| US-20040127424-A1 | Inhibitors of cruzipain and other cysteine proteases | AMURA THERAPUTICS LIMITED (GB) | 2004-07-01 | — | — | US | disclosed |
| EP-1358174-A2 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | Amura Therapeutics Limited (GB) | 2003-11-05 | — | — | EP | disclosed |
| WO-2002057248-A2 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | AMURA THERAPEUTICS LIMITED (GB) | 2002-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127424-A1 | Inhibitors of cruzipain and other cysteine proteases | CPN1, CTRL, CPA1 | ALDH1A1 2913/4885HPGD 2487/4885SMN1; SMN2 3151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.